IMGN151

Phase 2Small molecule

AbbVie

IMGN151 is one of 7 small molecule programs targeting Gynaecological Cancers. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gynaecological CancersActive, not recruiting

Gynecologic CancersRecruiting

Gynaecological CancersPhase 1

Active, not recruiting

Gynecologic CancersPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Gynecologic Cancers

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Phase 2

1 2

Avastin

Roche

Phase 2

1 3

Paraplatin

AAvyxa

Phase 2

1 4

Talzenna

Pfizer

Phase 1

1 5

IMGN151

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Gynaecological Cancers

NCT05527184

Q1 2028

Phase 2Recruiting

Gynecologic Cancers

NCT07024784

Clinical

Trials by Indication[1]

Gynaecological Cancers1 trial

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT05527184·256 enrolled

Gynecologic Cancers1 trial

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT07024784·377 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IMGN151. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMGN151 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMGN151. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AbbVie

IMGN151

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Trials by Indication[1]

Gynaecological Cancers1 trial

Gynecologic Cancers1 trial

References

Drug Info

Quick Facts

Related News